Form 4: enVVeno Medical Corp Chief Technology Officer Acquires 75,000 Stock Options
SEC Form 4
Hamed Alavi, Chief Technology Officer of enVVeno Medical Corp, was granted 75,000 stock options on December 18, 2024, which vest quarterly over three years.
Summary
- Hamed Alavi, the Chief Technology Officer of enVVeno Medical Corp, received 75,000 stock options on December 18, 2024.
- These options were granted under the company's Amended and Restated 2016 Omnibus Incentive Plan.
- The options have an exercise price of $2.57.
- The options vest in equal quarterly installments over three years, concluding in 2027.
- The options expire on December 18, 2034.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management interests with shareholders. There is no indication of any negative sentiment.
Positives
- The grant of stock options aligns the Chief Technology Officer's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the executive.
Industry Context
Stock option grants are a common form of executive compensation in the technology and medical device industries, used to incentivize performance and retain key talent.
Comparison to Industry Standards
- Stock option grants are a standard practice for incentivizing executives in publicly traded companies, particularly in the technology and medical device sectors.
- The vesting schedule of three years is typical for such grants, aligning with long-term performance goals.
- The exercise price of $2.57 is specific to enVVeno Medical Corp's stock and market conditions at the time of the grant.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it incentivizes the Chief Technology Officer to improve company performance.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 12/18/2024 | Date of stock option grant to Hamed Alavi. |
| 12/20/2024 | Date of filing of the SEC Form 4. |
| 2027 | End of the three year vesting period. |
| 12/18/2034 | Expiration date of the stock options. |
Keywords
stock options, executive compensation, insider trading, vesting, enVVeno Medical Corp, NVNO, Hamed Alavi
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.